# Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

> **NCT00006008** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** arsenic trioxide

## Key facts

- **NCT ID:** NCT00006008
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006008, "Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*